GFM
TERN

GF Fund Management’s Terns Pharmaceuticals TERN Stock Holding History

GF Fund Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107K Buy
2,023
+253
+14% +$10.4K ﹤0.01% 335
2025
Q4 		$71.5K Sell
1,770
-113
-6% -$2.61K ﹤0.01% 374
2025
Q3 		$14.1K Sell
1,883
-291
-13% -$1.86K ﹤0.01% 527
2025
Q2 		$8.11K Hold
2,174
– – ﹤0.01% 590
2025
Q1 		$6K Buy
2,174
+391
+22% +$1.6K ﹤0.01% 613
2024
Q4 		$9.88K Buy
+1,783
New +$12.1K ﹤0.01% 544

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

GF Fund Management's TERN Position: Q1 2026 in Review

GF Fund Management increased its Terns Pharmaceuticals (TERN) stake by 14% in Q1 2026, buying an estimated $10.4K and bringing the position to 2,023 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #335.

GF Fund Management first reported a position in TERN in Q4 2024 and has held it in 6 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • GF Fund Management held 2,023 shares of Terns Pharmaceuticals worth $107K as of Q1 2026.
  • GF Fund Management bought 253 Terns Pharmaceuticals shares in Q1 2026, an estimated $10.4K.
  • Terns Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #335 holding.
  • GF Fund Management first reported a position in Terns Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.